Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GILD Stock Forecast 2026-2027
$145.21
Current Price
$180.27B
Market Cap
Buy 22
Hold 7
Sell 1
Wall St Analyst Ratings
Distance to GILD Price Targets
+21.9%
To High Target of $177.00
+10.2%
To Median Target of $160.00
-18.7%
To Low Target of $118.00
GILD Price Momentum
+0.9%
1 Week Change
-6.3%
1 Month Change
+28.1%
1 Year Change
+18.3%
Year-to-Date Change
-7.7%
From 52W High of $157.29
+55.5%
From 52W Low of $93.37
📊 TOP ANALYST CALLS
Did GILD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Gilead is one of their latest high-conviction picks.
Latest GILD Stock Price Targets & Analyst Predictions
Based on our analysis of 41 Wall Street analysts, GILD has a bullish consensus with a median price target of $160.00 (ranging from $118.00 to $177.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $145.21, the median forecast implies a 10.2% upside. This outlook is supported by 22 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Louis Chen at Scotiabank, projecting a 21.9% upside. Conversely, the most conservative target is provided by Brian Abrahams at RBC Capital, suggesting a 18.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GILD Analyst Ratings
22
Buy
7
Hold
1
Sell
GILD Price Target Range
Low
$118.00
Average
$160.00
High
$177.00
Current: $145.21
Latest GILD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GILD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 10, 2026 | Jefferies | Akash Tewari | Buy | Initiates | $180.00 |
| Feb 23, 2026 | Needham | Joseph Stringer | Buy | Reiterates | $170.00 |
| Feb 20, 2026 | Barclays | Emily Field | Equal-Weight | Initiates | $155.00 |
| Feb 11, 2026 | Scotiabank | Louis Chen | Sector Outperform | Maintains | $177.00 |
| Feb 11, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $165.00 |
| Feb 11, 2026 | Cantor Fitzgerald | Carter Gould | Overweight | Maintains | $155.00 |
| Feb 11, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $152.00 |
| Feb 11, 2026 | Needham | Joseph Stringer | Buy | Maintains | $170.00 |
| Feb 11, 2026 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $118.00 |
| Jan 27, 2026 | Truist Securities | Gregory Renza | Buy | Maintains | $145.00 |
| Jan 27, 2026 | Citigroup | Geoff Meacham | Buy | Maintains | $156.00 |
| Jan 26, 2026 | UBS | Michael Yee | Buy | Maintains | $155.00 |
| Jan 13, 2026 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $150.00 |
| Jan 7, 2026 | Citigroup | Geoff Meacham | Buy | Maintains | $140.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $145.00 |
| Dec 12, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $151.00 |
| Dec 10, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $150.00 |
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Assumes | $140.00 |
| Nov 13, 2025 | Needham | Joseph Stringer | Buy | Maintains | $140.00 |
| Nov 13, 2025 | Scotiabank | Louis Chen | Sector Outperform | Initiates | $140.00 |
Gilead Sciences, Inc. (GILD) Competitors
The following stocks are similar to Gilead based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Gilead Sciences, Inc. (GILD) Financial Data
Gilead Sciences, Inc. has a market capitalization of $180.27B with a P/E ratio of 21.9x. The company generates $29.44B in trailing twelve-month revenue with a 28.9% profit margin.
Revenue growth is +4.7% quarter-over-quarter, while maintaining an operating margin of +37.4% and return on equity of +40.7%.
Valuation Metrics
Market Cap
$180.27B
Enterprise Value
$200.27B
P/E Ratio
21.9x
PEG Ratio
1.0x
Price/Sales
6.3x
Growth & Margins
Revenue Growth (YoY)
+4.7%
Gross Margin
+79.5%
Operating Margin
+37.4%
Net Margin
+28.9%
EPS Growth
+22.4%
Financial Health
Cash/Price Ratio
+5.3%
Current Ratio
1.6x
Debt/Equity
112.9x
ROE
+40.7%
ROA
+12.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Gilead Sciences, Inc. (GILD) Business Model
About Gilead Sciences, Inc.
What They Do
Biopharmaceutical company focused on innovative medicines.
Business Model
Gilead Sciences generates revenue by discovering, developing, and commercializing medicines for infectious diseases and oncology. Its core product offerings include treatments for HIV, hepatitis B, and hepatitis C, as well as cancer therapies acquired through strategic acquisitions. The company benefits from both blockbuster drugs and new therapies that meet significant medical needs, contributing to stable revenue streams.
Additional Information
With approximately 17,600 employees, Gilead is a key player in the healthcare sector, contributing to public health initiatives against infectious diseases and cancer. The company has recently received FDA approval for new products, positioning itself for potential growth in sales. Gilead is financially robust, with a consistent dividend policy that highlights its stability within the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,000
CEO
Mr. Daniel P. O'Day
Country
United States
IPO Year
1992
Website
www.gilead.comGilead Sciences, Inc. (GILD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Top Stock Reports for Oracle, T-Mobile & Gilead
Oracle's cloud infrastructure revenue jumped 84% in fiscal Q3 as AI and multicloud demand surged, though heavy data-center investments pushed trailing free cash flow to -$13.2B.
Mar 12, 2026
By Mark Vickery
Research Daily
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) reached $146.63 at the closing of the latest trading day, reflecting a +1.88% change compared to its last close.
Mar 09, 2026
By Zacks Equity Research
Tale of the Tape
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Mar 06, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Gilead Sciences, Inc. (GILD) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key developments and insights into its healthcare strategies.
Why It Matters
Gilead's presentation at a major healthcare conference can signal strategic plans or developments, influencing stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Two healthcare companies have demonstrated resilience against economic downturns and have consistently increased their dividends over the past decade, indicating stable financial performance.
Why It Matters
Stable dividends and resilience during downturns indicate strong financial health, making these healthcare leaders attractive options for risk-averse investors seeking reliable income.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Josh Brown, CEO of Ritholtz Wealth Management, stated on CNBC that large-cap biotech stocks are growth investments free from disruption concerns.
Why It Matters
Josh Brown's endorsement of large-cap biotech as stable growth stocks suggests potential resilience in this sector, attracting investors seeking reliable returns amid market volatility.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
3 days ago
Quick Summary
Gilead Sciences, Inc. (GILD) recently presented at the Leerink Global Healthcare Conference 2026, sharing insights relevant to investors in the healthcare sector.
Why It Matters
Gilead's presentation at a major healthcare conference signals potential developments in its pipeline, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Gilead Sciences (GILD) closed at $146.63, marking a 1.88% increase from the previous trading day.
Why It Matters
Gilead Sciences' stock increase indicates positive market sentiment, potentially signaling strong performance or investor confidence, which can influence future trading decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Jefferies has begun coverage of Gilead Sciences Inc., indicating renewed interest in the large-cap biopharma sector on Wall Street.
Why It Matters
Jefferies' initiation of coverage on Gilead Sciences may signal new investment opportunities and influence market sentiment, impacting stock performance and investor strategies in biopharma.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Frequently Asked Questions About GILD Stock
What is Gilead Sciences, Inc.'s (GILD) stock forecast for 2026?
Based on our analysis of 41 Wall Street analysts, Gilead Sciences, Inc. (GILD) has a median price target of $160.00. The highest price target is $177.00 and the lowest is $118.00.
Is GILD stock a good investment in 2026?
According to current analyst ratings, GILD has 22 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $145.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GILD stock?
Wall Street analysts predict GILD stock could reach $160.00 in the next 12 months. This represents a 10.2% increase from the current price of $145.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Gilead Sciences, Inc.'s business model?
Gilead Sciences generates revenue by discovering, developing, and commercializing medicines for infectious diseases and oncology. Its core product offerings include treatments for HIV, hepatitis B, and hepatitis C, as well as cancer therapies acquired through strategic acquisitions. The company benefits from both blockbuster drugs and new therapies that meet significant medical needs, contributing to stable revenue streams.
What is the highest forecasted price for GILD Gilead Sciences, Inc.?
The highest price target for GILD is $177.00 from Louis Chen at Scotiabank, which represents a 21.9% increase from the current price of $145.21.
What is the lowest forecasted price for GILD Gilead Sciences, Inc.?
The lowest price target for GILD is $118.00 from Brian Abrahams at RBC Capital, which represents a -18.7% decrease from the current price of $145.21.
What is the overall GILD consensus from analysts for Gilead Sciences, Inc.?
The overall analyst consensus for GILD is bullish. Out of 41 Wall Street analysts, 22 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $160.00.
How accurate are GILD stock price projections?
Stock price projections, including those for Gilead Sciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 10:58 AM UTC